Announcements Trials
Browse Landscape

Status

Recruiting 27Completed 24Unknown 13Terminated 9Active not recruiting 9Withdrawn 5Not yet recruiting 3Enrolling by invitation 3No longer available 2Approved for marketing 2Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Recurrence 11Carcinoma, Non-Small-Cell Lung 11Neoplasms 8Prostatic Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Leukemia, Myeloid, Acute 4Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lambert-Eaton Myasthenic Syndrome 3HER2-positive Breast Cancer 3Glioma 3Carcinoma, Medullary 3Thyroid Neoplasms 2Stomach Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Myasthenic Syndromes, Congenital 2Lymphoma 2Liver Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Head and Neck Neoplasms 2

Interventions

3-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × Paraganglioma × Clear all
NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡